Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04849364 |
|
Recruitment Status :
Recruiting
First Posted : April 19, 2021
Last Update Posted : November 13, 2023
|
Sponsor:
Bryan Schneider, MD
Collaborators:
Genentech, Inc.
Pfizer
Foundation Medicine
Indiana University
Vera Bradley Foundation for Breast Cancer Research
Information provided by (Responsible Party):
Bryan Schneider, MD, Hoosier Cancer Research Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2029 |
| Estimated Study Completion Date : | January 31, 2034 |